← back to search

Jian Zhang

Shandong University of Science and Technology · CN
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer-related molecular mechanisms research, Cancer Immunotherapy and Biomarkers, MicroRNA in disease regulation, and RNA modifications and cancer.
h-index
99
citations
50,367
works
2,120
NIH funding
primary concept
email

Recent publications

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study.
2026cited by 1position: contributordoi
DrugSurvPlot: A Novel Web-Based Platform Harnessing Drug Sensitivity Scores as Molecular Biomarkers for Pan-Cancer Survival Prognosis.
2026cited by 1position: contributordoi
PPP2R2C confers radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis via RPS27L stabilization.
2026cited by 0position: contributordoi
Integrating digital solutions improves mental health management in cancer care.
2026cited by 0position: contributordoi
KDM4B/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway.
2026cited by 0position: contributordoi
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.
2026cited by 0position: contributordoi
An Interpretable Multi-Task Whole-Slide Histopathology AI Model for Non-Small Cell Lung Cancer: Cross-Cohort Generalization, Spatial Attention–Transcriptomic Integration, and Molecular–Immune Profiling
2026cited by 0position: contributordoi
HGD-derived N-formylkynurenine promotes small cell lung cancer chemoresistance by activating ATL2-mediated endoplasmic reticulum remodelling.
2026cited by 0position: contributordoi
Renal adverse events in EGFR-TKI treatment: Comprehensive characterization of clinical patterns and molecular underpinnings
Genes & Diseases 2026cited by 0position: contributordoi
A Novel Mechanism of Salvianolic Acid B in Postmyocardial Infarction Cardiac Protection: PHB1‐Driven Raf‐ERK Pathway Activation Promotes Cardiomyocyte Mitosis
MedComm 2026cited by 0position: middledoi
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.
2025cited by 45position: contributordoi
Heterogeneity of Intratumoral Microbiota Within the Tumor Microenvironment and Relationship to Tumor Development
Med Research 2025cited by 41position: middledoi
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
Signal Transduction and Targeted Therapy 2025cited by 27position: middledoi
Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies
MedComm 2025cited by 26position: middledoi
The metabolic dialogue between intratumoural microbes and cancer: implications for immunotherapy.
2025cited by 21position: contributordoi
Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence.
2025cited by 20position: contributordoi
Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma.
2025cited by 20position: contributordoi
Cloud‐Based GWAS Platform: An Innovative Solution for Efficient Acquisition and Analysis of Genomic Data
Med Research 2025cited by 20position: contributordoi
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.
2025cited by 18position: contributordoi
Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies.
2025cited by 18position: contributordoi
T-cell Senescence in the Tumor Microenvironment
Cancer Immunology Research 2025cited by 18position: middledoi
Decoding the mechanisms behind second primary cancers.
2025cited by 13position: contributordoi
Tumor Electrophysiology in Precision Tumor Therapy
iMetaMed 2025cited by 13position: contributordoi
Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors.
2025cited by 12position: contributordoi
Targeting PFKFB4 Biomimetic Codelivery System Synergistically Enhances Ferroptosis to Suppress Small Cell Lung Cancer and Augments the Efficacy of Anti-PD-L1 Immunotherapy.
2025cited by 11position: contributordoi
Targeting PFKFB4 Biomimetic Codelivery System Synergistically Enhances Ferroptosis to Suppress Small Cell Lung Cancer and Augments the Efficacy of Anti‐PD‐L1 Immunotherapy
Advanced Science 2025cited by 11position: lastdoi
The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events
Med Research 2025cited by 10position: contributordoi
NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities.
2025cited by 9position: contributordoi
ROS-degradable hydrogel delivering LOXL2-LNPs rescues disc degeneration by synchronously suppressing cellular senescence and oxidative damage
Journal of Nanobiotechnology 2025cited by 8position: firstdoi
Evaluating generative AI models for explainable pathological feature extraction in lung adenocarcinoma: grading assessment and prognostic model construction.
2025cited by 7position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 54 papers (2019–2026)Hao Zhang · Northwestern Polytechnical University37 papers (2022–2024)Peng Luo · Clarivate PLC34 papers (2019–2026)Peng Luo · Harbin University of Science and Technology24 papers (2020–2025)Chunquan Li · Kunming University of Science and Technology22 papers (2016–2024)Quan Cheng · Central South University21 papers (2022–2025)Nan Zhang · The Wistar Institute21 papers (2022–2023)Zeyu Wang · Anhui University19 papers (2022–2024)Zaoqu Liu · Zhengzhou University17 papers (2022–2025)Anqi Lin · Zhujiang Hospital17 papers (2022–2026)Qiuyu Wang · Fudan University15 papers (2017–2023)Chenchen Feng · Fudan University15 papers (2017–2023)Quan Cheng · Clarivate PLC13 papers (2022–2026)Xuecang Li · Harbin Medical University13 papers (2017–2022)Fengcui Qian · Harbin Medical University12 papers (2018–2024)Bo Ai · Harbin Medical University12 papers (2017–2023)Xuefeng Bai · Harbin Medical University11 papers (2018–2022)Zaoqu Liu · Chinese Academy of Medical Sciences & Peking Union Medical College10 papers (2022–2025)Ziyu Dai · Central South University10 papers (2022–2023)Xigao Cheng · Nanchang University10 papers (2021–2025)